Clinical Trials
Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART RegimensConditions: Pediatric HIV; HIV InfectionsIntervention: Drug: Boosted Atazanavir Sponsors: Phoenix Children's Hospital; Bristol-Myers Squibb Completed Thu, 16 Jul 2009 12:00:00 EDT Atazanavir and Endothelial Function in Older HIV PatientsCondition: HIVInterventions: Drug: Atazanavir; Other: Placebo Sponsor: Brigham and Women's Hospital Completed Fri, 13 Jan 2017 12:00:00 EST Microboosting of Atazanavir 300 mg With 50 mg Versus 100mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic StudyCondition: HIV InfectionIntervention: Drug: atazanavir 300mg boosted with ritonavir 50 mg Sponsors: Ottawa Hospital Research Institute; Bristol-Myers Squibb Completed Tue, 14 Jan 2014 12:00:00 EST ATAGLU: Study of Glucose Metabolism in HIV Positive Patients That Switch From Another Protease Inhibitor to AtazanavirCondition: HIVIntervention: Drug: Atazanavir Sponsor: University of Roma La Sapienza Unknown status Wed, 02 Apr 2014 12:00:00 EDT Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric PatientsCondition: HIVInterventions: Drug: Atazanavir Sulphate; Drug: Ritonavir Sponsor: Bristol-Myers Squibb Completed Thu, 14 Apr 2011 12:00:00 EDT The Effects of Atazanavir-induced Hyperbilirubinemia During Human EndotoxemiaConditions: Endotoxemia; Inflammation; Multi Organ Dysfunction Syndrome; SepsisInterventions: Drug: Atazanavir; Drug: E. coli endotoxin Sponsor: Radboud University Completed Tue, 09 Jun 2009 12:00:00 EDT Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected PatientsCondition: HIV InfectionIntervention: Drug: maraviroc (300 mg QD) + atazanavir/ritonavir (300 and 200 mg /100 mg QD) Sponsor: University of Turin, Italy Withdrawn Wed, 17 Oct 2018 12:00:00 EDT Switch to Atazanavir and Brachial Artery Reactivity (SABAR) StudyConditions: HIV Infection; HyperlipidemiaInterventions: Drug: Atazanavir; Drug: current antiretroviral regimen Sponsors: Northwestern University; Bristol-Myers Squibb Completed Fri, 23 Sep 2005 12:00:00 EDT Atazanavir/r + Lamivudine Dual TherapyCondition: Human Immunodeficiency VirusIntervention: Drug: Atazanavir, ritonavir, lamivudine Sponsor: Catholic University of the Sacred Heart Completed Wed, 16 May 2012 12:00:00 EDT Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 CountsConditions: HIV-1 Infection; Immunosuppression-related Infectious DiseaseInterventions: Drug: DARUNAVIR; Drug: ATAZANAVIR Sponsor: Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba Completed Mon, 26 Aug 2013 12:00:00 EDT 
Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy SubjectsCondition: HIVInterventions: Drug: Atazanavir (current formulation); Drug: Atazanavir, powder for oral use 1 (POU1); Drug: Atazanavir (POU2) Sponsor: Bristol-Myers Squibb Completed Thu, 28 Jul 2011 12:00:00 EDT Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With CobicistatCondition: Human Immunodeficiency Virus Type 1 (HIV-1)Interventions: Drug: Atazanavir; Drug: Cobicistat; Drug: Atazanavir/Cobicistat FDC Sponsor: Bristol-Myers Squibb Completed Tue, 23 Apr 2013 12:00:00 EDT Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric PatientsCondition: HIV, PediatricInterventions: Drug: Atazanavir; Drug: Ritonavir Sponsor: Bristol-Myers Squibb Completed Tue, 25 Sep 2012 12:00:00 EDT Raltegravir and Atazanavir Dosing Strategy StudyCondition: HIV InfectionIntervention: Drug: atazanavir plus raltegravir Sponsor: Kirby Institute Completed Thu, 02 Apr 2009 12:00:00 EDT Atazanavir Twice DailyConditions: HIV Infections; Protease InhibitorIntervention: Drug: Atazanavir Sulphate Sponsor: Bristol-Myers Squibb Completed Thu, 27 Jul 2006 12:00:00 EDT Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy SubjectsConditions: HIV Infections; Protease InhibitorInterventions: Drug: Atazanavir Sulphate + Ritonavir; Drug: Atazanavir Sulphate + Ritonavir + Efavirenz Sponsor: Bristol-Myers Squibb Completed Thu, 27 Jul 2006 12:00:00 EDT Atazanavir or Boosted Atazanavir Substitution for Ritonavir Boosted PI in Patients With HyperlipidemiaConditions: Hyperlipidemia; HIV InfectionsIntervention: Drug: Atazanavir Sponsors: Stanford University; Bristol-Myers Squibb Completed Mon, 12 Sep 2005 12:00:00 EDT PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)Condition: HIV InfectionsInterventions: Drug: Atazanavir powder; Drug: Ritonavir oral solution; Drug: Atazanavir capsules; Drug: Ritonavir capsules Sponsor: Bristol-Myers Squibb Completed Wed, 07 Apr 2010 12:00:00 EDT Effects of Atazanavir Treatment on Type 2 Diabetes Mellitus Related Endothelial DysfunctionCondition: Type 2 Diabetes Mellitus Related Endothelial DysfunctionInterventions: Drug: placebo + atazanavir; Drug: atazanavir + placebo Sponsors: Radboud University; Dutch Diabetes Research Foundation Completed Fri, 13 Jun 2008 12:00:00 EDT Switch to Unboosted Atazanavir With Tenofovir StudyCondition: HIV InfectionInterventions: Drug: atazanavir; Drug: atazanavir/ritonavir Sponsor: University of British Columbia Completed Wed, 11 May 2011 12:00:00 EDT
Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral SuppressionCondition: HIV-1 InfectionIntervention: Drug: Atazanavir/ritonavir monotherapy Sponsors: Ospedale San Raffaele; Bristol-Myers Squibb Completed Thu, 19 Jan 2012 12:00:00 EST Metabolic Effects of Switching Kaletra to Boosted ReyatazCondition: HIV InfectionsInterventions: Drug: atazanavir/ritonavir; Drug: lopinavir/ritonavir Sponsors: Massachusetts General Hospital; Bristol-Myers Squibb Completed Tue, 19 Dec 2006 12:00:00 EST Comparing the Effectiveness Between Ritonavir Boosted Atazanavir and Efavirenz for the First HIV TreatmentCondition: HIV InfectionInterventions: Drug: atazanavir arm; Drug: efavirenz Sponsors: International Medical Center of Japan; Ministry of Health, Labour and Welfare, Japan Completed Tue, 24 Jan 2006 12:00:00 EST Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected PatientsCondition: HIV-1 InfectionIntervention: Drug: Atazanavir 200 mg/r Sponsors: Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida; INSERM UMR S 1136 Completed Tue, 16 Jun 2015 12:00:00 EDT Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic SuppressionCondition: Human Immunodeficiency Virus (HIV) InfectionsIntervention: Drug: Atazanavir + Ritonavir Sponsor: Bristol-Myers Squibb Completed Fri, 16 Jun 2006 12:00:00 EDT Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study)Condition: HIV InfectionsInterventions: Drug: Atazanavir + 2 NRTIs; Drug: Atazanavir + Ritonavir + 2 NRTIs Sponsor: Bristol-Myers Squibb Completed Wed, 21 Sep 2005 12:00:00 EDT Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy ParticipantsConditions: Human Immunodeficiency Virus Type 1 (HIV-1); HIV InfectionsInterventions: Drug: Voriconazole; Drug: Atazanavir; Drug: Ritonavir Sponsor: Bristol-Myers Squibb Completed Mon, 02 Feb 2009 12:00:00 EST NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 InfectionConditions: Coronavirus Infection; Severe Acute Respiratory Infection; Severe Acute Respiratory Syndrome Coronavirus 2Interventions: Drug: Drug: NA-831; Combination Product: NA-831 and Atazanavir; Combination Product: NA-831and Dexamethasone; Combination Product: Atazanavir and Dexamethasone Sponsor: NeuroActiva, Inc. Recruiting Tue, 30 Jun 2020 12:00:00 EDT A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable ViremiaCondition: HIV-1 InfectionIntervention: Drug: atazanavir 300 mg + ritonavir 100 mg + dolutegravir 50 mg Sponsors: Castagna Antonella; Bristol-Myers Squibb; ViiV Healthcare Unknown status Mon, 07 Sep 2015 12:00:00 EDT Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic SuppressionConditions: HIV Infection; Mitochondrial DysfunctionInterventions: Drug: Atazanavir/ritonavir; Drug: Efavirenz Sponsors: The Cleveland Clinic; National Institute of Allergy and Infectious Diseases (NIAID); Case Western Reserve University; Bristol-Myers Squibb Terminated Fri, 03 Sep 2010 12:00:00 EDT
A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/RitonavirCondition: HIVInterventions: Drug: Lopinavir; Drug: Atazanavir Sponsors: ANRS, Emerging Infectious Diseases; European and Developing Countries Clinical Trials Partnership (EDCTP); Ludwig-Maximilians - University of Munich; Institute of Tropical Medicine, Belgium; Institut de Recherche pour le Developpement, France; Swiss National Science Foundation; University of Limpopo; NIMR-Mbeya Medical Research Program (MMRP)/ Mbeya Referral Hospital, Tanzania Withdrawn Tue, 07 Dec 2010 12:00:00 EST Pharmacokinetic Interactions Between Telaprevir and Un-boosted AtazanavirConditions: Hepatitis C, Chronic; HIV InfectionInterventions: Drug: Ritonavir withdrawal, atazanavir 200 mg/12h; Drug: Telaprevir interactions Sponsors: Hospitales Universitarios Virgen del Rocío; Bristol-Myers Squibb Completed Wed, 27 Mar 2013 12:00:00 EDT Pharmacokinetics of Atazanavir in Special PopulationsConditions: HIV/AIDS; TuberculosisInterventions: Drug: Atazanavir 300mg/ Ritonavir 100 mg once daily; Drug: Atazanavir 250 mg / ritonavir 80 mg Sponsors: University of Liverpool; Infectious Diseases Institute, Makerere University College of Health Sciences; Joint Clinical Research Centre- Kampala; Desmond Tutu HIV Foundation; University of Cape Town; European and Developing Countries Clinical Trials Partnership (EDCTP) - funder Active, not recruiting Mon, 22 Apr 2019 12:00:00 EDT Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant WomenCondition: HIV InfectionIntervention: Drug: Atazanavir + Ritonavir + Combivir Sponsor: Bristol-Myers Squibb Completed Wed, 17 May 2006 12:00:00 EDT Effect of Atazanavir-ritonavir on the Pharmacokinetics and Toxicity of LumefantrineCondition: Drug InteractionInterventions: Drug: Artemether-lumefantrine; Drug: Atazanavir-ritonavir 300/100 mg Sponsors: Fogarty International Center of the National Institute of Health; NIH Office of AIDS Research (OAR); National Institute on Minority Health and Health Disparities (NIMHD); National Institute of Neurological Disorders and Stroke (NINDS) Completed Fri, 28 Aug 2020 12:00:00 EDT Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive PatientsCondition: HIV InfectionsInterventions: Drug: Atazanavir/ Stavidine / Lamivudine; Drug: Atazanavir-Ritonavir/ Stavidine / Lamivudine Sponsor: Bristol-Myers Squibb Completed Fri, 11 Jun 2004 12:00:00 EDT Study to Evaluate the Influence of Nevirapine to Atazanavir in Steady State Equilibrium in HIV PatientsCondition: HIV InfectionsInterventions: Drug: Atazanavir (Reyataz); Drug: Ritonavir (Norvir); Drug: Nevirapine (Viramune) Sponsors: Germans Trias i Pujol Hospital; Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia; Hospital San Jaime de Calella Completed Tue, 25 Jul 2006 12:00:00 EDT Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance RegimenCondition: HIV-1 InfectionInterventions: Drug: Atazanavir; Drug: Dolutegravir; Drug: Lamivudine Sponsor: Radboud University Terminated Fri, 02 Oct 2015 12:00:00 EDT Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail StudyConditions: HIV; HIV InfectionsIntervention: Drug: darunavir/ritonavir then atazanavir/ritonavir Sponsor: St Stephens Aids Trust Completed Tue, 23 Feb 2010 12:00:00 EST Phase IIB Pilot of Atazanavir + RaltegravirCondition: HIVInterventions: Drug: Atazanavir; Drug: Raltegravir; Drug: Ritonavir; Drug: Tenofovir/Emtricitabine Sponsors: Bristol-Myers Squibb; Merck Sharp & Dohme Corp. Terminated Wed, 08 Oct 2008 12:00:00 EDT
A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes MellitusCondition: Type 1 Diabetes MellitusIntervention: Drug: Atazanavir Sponsors: Brigham and Women's Hospital; National Institutes of Health (NIH) Completed Mon, 22 Aug 2011 12:00:00 EDT A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)Condition: Infection, Human Immunodeficiency VirusInterventions: Drug: Reyataz + Norvir + Truvada; Drug: Reyataz + Epzicom Sponsors: ViiV Healthcare; GlaxoSmithKline Completed Tue, 13 Apr 2010 12:00:00 EDT A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral TherapyCondition: HIV InfectionsInterventions: Drug: Atazanavir (immediate switch); Drug: Atazanavir (Week 24 switch) Sponsor: Bristol-Myers Squibb Completed Thu, 28 Aug 2003 12:00:00 EDT Boosted Atazanavir and Truvada Given Once-Daily - BATON StudyCondition: HIV InfectionsInterventions: Drug: Truvada; Drug: Atazanavir; Drug: Ritonavir Sponsor: Gilead Sciences Completed Fri, 23 Sep 2005 12:00:00 EDT Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV InfectionCondition: HIVInterventions: Drug: Atazanavir; Drug: Ritonavir; Drug: Tenofovir (TDF); Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI); Drug: Famotidine (FAM) Sponsor: Bristol-Myers Squibb Completed Tue, 02 Nov 2010 12:00:00 EDT Effect of Atazanavir on Endothelial Function in HIV-Infected PatientsConditions: HIV Infections; DyslipidemiaIntervention: Drug: ATAZANAVIR Sponsors: Foundation for Cardiovascular Research, Zurich; Bristol-Myers Squibb Completed Wed, 14 Mar 2007 12:00:00 EDT Pharmacokinetic Study of Two HIV Protease Inhibitors in PatientsCondition: HIV InfectionInterventions: Drug: atazanavir; Drug: lopinavir/ritonavir Sponsors: University of Oklahoma; Abbott Terminated Thu, 11 Jan 2007 12:00:00 EST Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected PatientsCondition: HIV InfectionsInterventions: Drug: Raltegravir and truvada; Drug: Atazanavir, Norvir and Truvada Sponsors: The University of Texas Health Science Center, Houston; Merck Sharp & Dohme Corp. Completed Tue, 30 Sep 2008 12:00:00 EDT "The Once A Day Protease Inhibitor Regimens"Condition: HIV InfectionsInterventions: Drug: ritonavir-boosted atazanavir; Drug: ritonavir-boosted fosamprenavir Sponsor: The University of Texas Health Science Center, Houston Completed Wed, 19 Oct 2005 12:00:00 EDT Genetics and HIV-1 Protease InhibitorsCondition: HIVIntervention: Drug: Atazanavir Sponsors: University of Colorado, Denver; National Institute of Allergy and Infectious Diseases (NIAID) Completed Wed, 06 Jul 2011 12:00:00 EDT
A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same TimeCondition: Healthy VolunteersInterventions: Drug: Atazanavir/Cobicistat; Drug: Atazanavir; Drug: Cobicistat Sponsor: Bristol-Myers Squibb Not yet recruiting Mon, 10 Feb 2020 12:00:00 EST The Nitazoxanide Plus Atazanavir for COVID-19 StudyCondition: Covid-19Interventions: Drug: Nitazoxanide and atazanavir/ritonavir; Other: Standard of Care Sponsors: Obafemi Awolowo University; University of Liverpool; African Centre of Excellence for Genomics of Infectious Diseases; Infectious Disease Hospital Olodo; Obafemi Awolowo University Teaching Hospitals Complex; Osun State Ministry of Health; Olabisi Onabanjo University Teaching Hospital Recruiting Tue, 07 Jul 2020 12:00:00 EDT Effects of Gastric pH on the Pharmacokinetics of AtazanavirCondition: HealthyInterventions: Drug: Ritonavir-boosted Atazanavir; Drug: Ritonavir-boosted Atazanavir plus Rabeprazole; Drug: Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine Hydrochloride Sponsor: University of California, San Francisco Completed Thu, 03 Jan 2013 12:00:00 EST A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic SyndromeCondition: HIV InfectionsIntervention: Drug: Atazanavir Sponsor: Bristol-Myers Squibb Terminated Tue, 11 Apr 2006 12:00:00 EDT Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected PatientsCondition: HIV, Combination TherapyInterventions: Drug: Atazanavir; Drug: Ritonavir (heat-stable); Drug: Raltegravir; Drug: Tenofovir/Emtricitabine Sponsor: Bristol-Myers Squibb Completed Mon, 11 Apr 2011 12:00:00 EDT Study of Reyataz in HIV-infected Patients With Lipodystrophy SyndromeCondition: HIV-Associated Lipodystrophy SyndromeInterventions: Drug: Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs); Drug: continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs) Sponsor: Bristol-Myers Squibb Completed Fri, 26 Aug 2005 12:00:00 EDT A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIVConditions: Infection, Human Immunodeficiency Virus I; HIV InfectionInterventions: Drug: Trizivir; Drug: atazanavir; Drug: Combivir Sponsor: GlaxoSmithKline Completed Mon, 10 May 2004 12:00:00 EDT Taste Properties of Atazanavir and CobicistatCondition: HIV in AdultsInterventions: Drug: Atazanavir; Drug: Cobicistat; Drug: Active Pharmaceutical Ingredient Sponsor: Bristol-Myers Squibb Unknown status Thu, 04 Dec 2014 12:00:00 EST Atazanavir and Lamivudine for Treatment SimplificationCondition: HIV InfectionsInterventions: Drug: Lamiduvine (Epivir); Drug: Atazanavir (Reyataz); Drug: Ritonavir (Norvir) Sponsor: Catholic University of the Sacred Heart Completed Wed, 22 Apr 2009 12:00:00 EDT Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With OsteopeniaCondition: Human Immunodeficiency VirusInterventions: Drug: Boosted atazanavir; Drug: Lamivudine Sponsors: David Garcia Cinca; Fundacion Clinic per a la Recerca Biomédica Unknown status Tue, 12 Jan 2016 12:00:00 EST
GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and AtazanavirCondition: Healthy VolunteerInterventions: Drug: GSK1349572; Drug: Atazanavir 300 mg; Drug: Atazanavir 400 mg; Drug: Ritonavir Sponsors: GlaxoSmithKline; Shionogi Completed Mon, 20 Apr 2009 12:00:00 EDT Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to RaltegravirConditions: HIV Infection; OsteopeniaInterventions: Drug: raltegravir and atazanavir and ritonavir; Drug: tenofovir/emtricitabine and atazanavir and ritonavir Sponsors: Giovanni Di Perri; University of Turin, Italy; University of Milan Terminated Thu, 18 Jul 2013 12:00:00 EDT SSAT067 PK of Atazanavir/Cobicistat and Darunavir/CobicistatCondition: HIVInterventions: Drug: Evotaz; Drug: Rezolsta Sponsors: St Stephens Aids Trust; Bristol-Myers Squibb Completed Wed, 28 Oct 2015 12:00:00 EDT Pharmacokinetic Study of 2 Doses of ATV/r OD + 2 NRTIs in Thai HIV-1 Infected PatientsCondition: HIV InfectionsIntervention: Drug: Atazanavir Sponsors: The HIV Netherlands Australia Thailand Research Collaboration; Bristol-Myers Squibb Completed Fri, 15 Dec 2006 12:00:00 EST Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat TrialsConditions: Solid Tumor; Hematological MalignanciesInterventions: Drug: Belinostat; Drug: Atazanavir Sponsors: Acrotech Biopharma LLC; Axis Clinicals Limited Recruiting Wed, 04 Dec 2019 12:00:00 EST A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/CobicistatConditions: Hepatitis C; HIVInterventions: Drug: Daclatasvir; Drug: Atazanavir; Drug: Ritonavir; Drug: Cobicistat Sponsor: Radboud University Completed Thu, 01 Oct 2015 12:00:00 EDT Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIVCondition: HIV InfectionsInterventions: Drug: Atazanavir + ritonavir + tenofovir + nucleoside; Drug: Atazanavir + saquinavir + tenofovir + nucleoside; Drug: Lopinavir/ritonavir + tenofovir + nucleoside Sponsor: Bristol-Myers Squibb Completed Wed, 08 May 2002 12:00:00 EDT Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current TreatmentCondition: HIV InfectionsIntervention: Drug: Raltegravir and Atazanavir Sponsor: Peter J. Ruane, M.D., Inc. Unknown status Thu, 11 Sep 2008 12:00:00 EDT Drug Interaction StudyCondition: Antivirals/HIVInterventions: Drug: Rifabutin; Drug: Rifabutin + Atazanavir + Ritonavir Sponsor: Bristol-Myers Squibb Completed Mon, 31 Mar 2008 12:00:00 EDT Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/rCondition: HIV InfectionsInterventions: Drug: ATV/r; Drug: DRV/r Sponsors: Community Research Initiative of New England; Tibotec Pharmaceutical Limited Completed Mon, 22 Sep 2008 12:00:00 EDT
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance TherapyCondition: HIV InfectionInterventions: Drug: Ritonavir boosted Atazanavir + Lamivudine; Drug: Ritonavir boosted Atazanavir + 2 NRTIs Sponsors: Fundacion SEIMC-GESIDA; Bristol-Myers Squibb Completed Thu, 03 Mar 2011 12:00:00 EST Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy FemalesCondition: HIV InfectionsInterventions: Drug: Ortho Tri-Cyclen (ethinyl estradiol + norgestimate); Drug: Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days Sponsor: Bristol-Myers Squibb Completed Thu, 27 Jul 2006 12:00:00 EDT DDI HV (ATV - Merck)Condition: HIV InfectionsInterventions: Drug: Raltegravir; Drug: Atazanavir; Drug: Atazanavir + Raltegravir Sponsors: Bristol-Myers Squibb; Merck Sharp & Dohme Corp. Completed Mon, 20 Aug 2007 12:00:00 EDT Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/RitonavirCondition: HIV InfectionsInterventions: Drug: atazanavir/ritonavir +2 NRTIs (immediate Switch Group); Drug: LPV/r +2 NRTIs (Delayed/optional Switch Group) Sponsor: Bristol-Myers Squibb Completed Mon, 18 Jul 2005 12:00:00 EDT Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug UsersConditions: HIV Infections; Hepatitis CInterventions: Drug: Raltegravir; Drug: Atazanavir/Ritonavir Sponsor: St. James's Hospital, Ireland Unknown status Fri, 16 Apr 2010 12:00:00 EDT BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose TruvadaCondition: HIV InfectionsInterventions: Drug: ATV; Drug: RTV; Drug: Tenofovi-Emtricitabine (TDF/FTC) tablet; Drug: LPV Sponsor: Bristol-Myers Squibb Completed Mon, 09 Jan 2006 12:00:00 EST Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive AdultsCondition: HIV InfectionsInterventions: Drug: nevirapine bid; Drug: nevirapine qd; Drug: atazanavir Sponsor: Boehringer Ingelheim Completed Wed, 18 Oct 2006 12:00:00 EDT Bioequivalence Study of Atazanavir 300 mg CapsuleCondition: HIV InfectionsIntervention: Drug: Atazanavir + Ritonavir Sponsor: Bristol-Myers Squibb Completed Fri, 27 Oct 2006 12:00:00 EDT Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected PatientsConditions: HIV Infection; HIV InfectionsInterventions: Drug: raltegravir QD; Drug: atazanavir; Drug: lamivudine (or emtricitabine) Sponsor: Radboud University Completed Wed, 22 Jul 2009 12:00:00 EDT BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.Condition: HIVInterventions: Drug: atazanavir/raltegravir; Drug: atazanavir/tenofovir/emtricitabine Sponsors: Community Research Initiative of New England; Bristol-Myers Squibb; Merck Sharp & Dohme Corp. Completed Thu, 02 Jul 2009 12:00:00 EDT
Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk FactorsCondition: Endothelial DysfunctionInterventions: Drug: Atazanavir; Drug: Lopinavir/ritonavir; Drug: Placebo Sponsors: Indiana University; National Heart, Lung, and Blood Institute (NHLBI) Completed Wed, 23 Jul 2008 12:00:00 EDT A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease InhibitorCondition: HIV InfectionsInterventions: Drug: Atazanavir; Drug: Nelfinavir mesylate Sponsor: Bristol-Myers Squibb Terminated Tue, 11 Dec 2001 12:00:00 EST Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIVCondition: HIVInterventions: Drug: 3 drug regimen: Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir; Drug: Ritonavir, Atazanavir, Truvada Sponsors: Kenneth H. Mayer, MD; Bristol-Myers Squibb; Gilead Sciences; Abbott Terminated Mon, 21 May 2012 12:00:00 EDT A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART RegimenCondition: HIV InfectionsInterventions: Drug: Atazanavir+ritonavir; Drug: Lopinavir+ritonavir Sponsor: Bristol-Myers Squibb Completed Fri, 26 Aug 2005 12:00:00 EDT Atazanavir/Ritonavir Maintenance TherapyCondition: HIV InfectionsInterventions: Drug: Atazanavir; Drug: Ritonavir Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Completed Mon, 07 Jun 2004 12:00:00 EDT A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected PatientsCondition: Human Immunodeficiency Virus-1Intervention: Drug: maraviroc Sponsors: ViiV Healthcare; Pfizer Completed Thu, 22 Jan 2009 12:00:00 EST Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate RosiglitazoneCondition: HIV InfectionsInterventions: Drug: Rosiglitazone maleate; Drug: Atazanavir Sulphate; Drug: Atazanavir Sulphate + Rosiglitazone maleate; Drug: Atazanavir Sulphate + Ritonavir; Drug: Atazanavir Sulphate + Ritonavir + Rosiglitazone maleate Sponsor: Bristol-Myers Squibb Completed Thu, 10 Aug 2006 12:00:00 EDT Two Clinical Trials to Evaluate Pharmacokinetics of Unboosted and Boosted Atazanavir Used Alone or Co-administered With Tenofovir DF in Healthy Korean and Caucasian Male VolunteersCondition: AtazanavirInterventions: Drug: atazanavir; Drug: Atazanavir(ATZ) and Tenofovir(TDF); Drug: Atazanavir(ATZ) + Ritonavir; Drug: atazanavir(ATZ) + tenofovir(TDF) + ritonavir Sponsors: Asan Medical Center; Bristol-Myers Squibb Unknown status Wed, 08 Jun 2011 12:00:00 EDT Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 InfectionConditions: Infection, Human Immunodeficiency Virus I; HIV InfectionInterventions: Drug: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r); Drug: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) Sponsors: ViiV Healthcare; GlaxoSmithKline Completed Tue, 27 Feb 2007 12:00:00 EST Safety Study of Raltegravir in HIV/HCV Co-infected PatientsConditions: HIV; Hepatitis CInterventions: Drug: raltegravir; Drug: Atazanavir/ritonavir Sponsors: University Hospital, Bonn; Dr. Axel Baumgarten, Berlin; Dr. Christoph Stephan, Frankfurt/M; Dr. Stefan Esser, Essen; Dr. Keikawus Arastéh, Berlin; Prof. Dr. Hans-Jürgen Stellbrink, Hamburg; Dr. Thomas Lutz, Frankfurt/M; Dr. Jörg Gölz , Berlin Withdrawn Thu, 21 Oct 2010 12:00:00 EDT
Roll-Over Protocol To Provide Atv And/Or Truvada For Extended AccessCondition: HIVInterventions: Drug: Atazanavir; Drug: Atazanavir/Ritonavir; Drug: Tenofovir/Emtricitabine; Drug: Lopinavir/ritonavir Sponsor: Bristol-Myers Squibb Completed Thu, 29 Oct 2009 12:00:00 EDT Atazanavir for HIV Infected Individuals: An Early Access ProgramCondition: HIV InfectionsIntervention: Drug: Atazanavir (BMS-232632) Sponsor: Bristol-Myers Squibb No longer available Mon, 30 Sep 2002 12:00:00 EDT A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing RegimenCondition: HIV InfectionsIntervention: Drug: Atazanvir/ritonavir + efavirenz Sponsor: Bristol-Myers Squibb Completed Fri, 26 Aug 2005 12:00:00 EDT RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected PatientsCondition: Chronic Infection With HIVInterventions: Drug: Ritonavir boosted Atazanavir; Drug: Raltegravir; Drug: TDF/FTC (or 3TC) Sponsors: Pedro Cahn; Merck Sharp & Dohme Corp. Unknown status Thu, 11 Apr 2013 12:00:00 EDT Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)Condition: HIV InfectionsInterventions: Drug: Atazanavir; Drug: Lopinavir/Ritonavir Sponsor: Bristol-Myers Squibb Completed Fri, 21 Dec 2001 12:00:00 EST Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received TreatmentCondition: HIVInterventions: Drug: ritonavir; Drug: darunavir; Drug: emtricitabine [FTC]/tenofovir [TDF]; Drug: atazanavir Sponsors: Tibotec, Inc; Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA Completed Tue, 23 Sep 2008 12:00:00 EDT Comparison of Epzicom and Truvada for the Initial Once Daily HIV TreatmentCondition: HIV InfectionsInterventions: Drug: lamivudine, abacavir , ritonavir, atazanavir; Drug: emtricitabine, tenofovir, ritonavir, atazanavir Sponsors: International Medical Center of Japan; Ministry of Health, Labour and Welfare, Japan Completed Tue, 16 Oct 2007 12:00:00 EDT BASIC: Boosted Atazanavir or Saquinavir Induced Lipid ChangesCondition: HIV InfectionsInterventions: Drug: saquinavir/ritonavir; Drug: atazanavir/ritonavir Sponsors: International Antiviral Therapy Evaluation Center; Hoffmann-La Roche; Gilead Sciences Completed Wed, 18 Oct 2006 12:00:00 EDT Pharmacokinetics, Safety & Tolerability of Isotopologs of Atazanavir (ATV), With Pharmacokinetic Comparison to ReyatazCondition: Healthy VolunteersInterventions: Drug: C-10276; Drug: C-10297; Drug: C-10299; Drug: Reyataz® Sponsor: Concert Pharmaceuticals Completed Tue, 25 Oct 2011 12:00:00 EDT Pilot Study of a Raltegravir Based NRTI Sparing RegimenConditions: Acquired Immune Deficiency Syndrome; AIDS; Human Immunodeficiency Virus; HIV InfectionsInterventions: Drug: Raltegravir; Drug: Atazanavir; Other: Standard treatment regimen Sponsors: Yale University; Bristol-Myers Squibb; Merck Sharp & Dohme Corp. Completed Thu, 25 Dec 2008 12:00:00 EST
ATV/Ritonavir Nevirapine Interaction (USPAC)Condition: HIV InfectionsInterventions: Drug: Nevirapine; Drug: Nevirapine + Atazanavir/Ritonavir; Drug: Atazanavir + Ritonavir Sponsor: Bristol-Myers Squibb Completed Tue, 13 Sep 2005 12:00:00 EDT Atazanavir or Lopinavir in HIV Post-exposure ProphylaxisCondition: HIV InfectionsInterventions: Drug: Combivir+Kaletra; Drug: Combivir+Reyataz Sponsor: Hospital Clinic of Barcelona Completed Wed, 11 Oct 2006 12:00:00 EDT Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and TruvadaCondition: HIV InfectionsInterventions: Drug: Atazanavir; Drug: Ritonavir; Drug: Tenofovir/emtricitabine Sponsors: French National Agency for Research on AIDS and Viral Hepatitis; Bristol-Myers Squibb; Gilead Sciences Completed Tue, 11 Sep 2007 12:00:00 EDT Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced AdultsConditions: HIV; HIV Infections; Acquired Immunodeficiency SyndromeInterventions: Drug: TAF; Drug: Placebo; Drug: E/C/F/TAF; Drug: Current failing ARV regimen; Drug: ATV Sponsor: Gilead Sciences Completed Wed, 23 Oct 2013 12:00:00 EDT Pharmacokinetic Study in Healthy Adult Volunteers to Assess the Interactions Between Steady-State Tipranavir and Atazanavir in the Presence of RitonavirCondition: HealthyInterventions: Drug: Tipranavir; Drug: Ritonavir; Drug: Atazanavir Sponsor: Boehringer Ingelheim Completed Wed, 01 Oct 2014 12:00:00 EDT Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)Condition: HIV InfectionsInterventions: Drug: tenofovir DF 300 mg QD; Drug: emtricitabine 200 mg QD; Drug: Nevirapine 200 mg BID; Drug: Atazanavir 300 mg; Drug: Ritonavir 100 mg Sponsor: Boehringer Ingelheim Completed Thu, 01 Nov 2007 12:00:00 EDT Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected AdultsConditions: HIV Infections; TuberculosisInterventions: Drug: Atazanavir; Drug: Rifampin; Drug: Ritonavir Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); AIDS Clinical Trials Group Completed Wed, 17 Nov 2004 12:00:00 EST Atazavanir/Ritonavir-based HAART in ChildrenCondition: HIVIntervention: Drug: boosted atazanavir (ATV/r) Sponsors: The HIV Netherlands Australia Thailand Research Collaboration; amfAR, The Foundation for AIDS Research; National Health Security Office, Thailand; The Thai Government Pharmaceutical Organization (GPO) Completed Thu, 02 Aug 2012 12:00:00 EDT Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous TreatmentCondition: HIV InfectionsInterventions: Drug: Atazanavir; Drug: Ritonavir; Drug: Saquinavir Sponsor: Bristol-Myers Squibb Completed Fri, 31 Aug 2001 12:00:00 EDT Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected PopulationCondition: Human Immunodeficiency VirusInterventions: Drug: tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV); Drug: tenofovir/emtricitabine (TDF/FTC); Drug: Atazanavir (ATV); Drug: Ritonavir; Procedure: Phlebotomy Sponsors: University of North Carolina, Chapel Hill; National Institute of Allergy and Infectious Diseases (NIAID) Completed Wed, 11 Aug 2010 12:00:00 EDT
Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected PatientsCondition: HIV InfectionsInterventions: Drug: Atazanavir/Ritonavir; Drug: Atazanavir/Ritonavir + Famotidine; Drug: Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine Sponsor: Bristol-Myers Squibb Completed Fri, 06 Oct 2006 12:00:00 EDT A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-LamivudineCondition: HIV InfectionsInterventions: Drug: Atazanavir; Drug: Lamivudine/Zidovudine; Drug: Efavirenz Sponsor: Bristol-Myers Squibb Completed Fri, 31 Aug 2001 12:00:00 EDT A Study of Drug-Drug Interaction Between Danoprevir Coadministered With Low-Dose Ritonavir and Tenofovir Disoproxil Fumarate or AtazanavirCondition: Healthy VolunteerInterventions: Drug: atazanavir; Drug: danoprevir; Drug: ritonavir; Drug: tenofovir disoproxil fumarate Sponsor: Hoffmann-La Roche Completed Mon, 07 May 2012 12:00:00 EDT TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV PatientsConditions: HIV Infections; Acquired Immunodeficiency SyndromeInterventions: Drug: Atazanavir (ATV) 300 mg; Drug: Atazanavir (ATV) 400 mg; Drug: Ritonavir (rtv) 100 mg; Drug: Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs); Drug: Etravirine (ETR) 200 mg; Drug: Tenofovir disoproxil fumarate (TDF) 300 mg Sponsor: Janssen R&D Ireland Completed Mon, 11 May 2009 12:00:00 EDT Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected PatientsCondition: HIV-1Interventions: Drug: Darunavir / Ritonavir + Tenofovir / Emtricitabine; Drug: Atazanavir / Ritonavir + Tenofovir / Emtricitabine Sponsor: Juan A. Arnaiz Completed Wed, 12 Jan 2011 12:00:00 EST Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI BackboneCondition: HIVInterventions: Drug: Atazanavir; Drug: Darunavir; Drug: Ritonavir; Drug: Optimized NRTI backbone Sponsor: Bristol-Myers Squibb Withdrawn Thu, 24 May 2012 12:00:00 EDT Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsConditions: HIV; HIV InfectionsInterventions: Drug: COBI; Drug: RTV; Drug: ATV; Drug: FTC/TDF; Drug: COBI placebo; Drug: RTV placebo Sponsor: Gilead Sciences Completed Thu, 22 Apr 2010 12:00:00 EDT Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsCondition: HIV-1 InfectionInterventions: Drug: COBI; Drug: RTV; Drug: ATV; Drug: FTC/TDF; Drug: COBI placebo; Drug: RTV placebo Sponsor: Gilead Sciences Completed Mon, 04 May 2009 12:00:00 EDT Korean Post-marketing Surveillance for Reyataz®Condition: HIV-1Intervention: Drug: No Intervention Sponsor: Bristol-Myers Squibb Completed Wed, 12 Oct 2011 12:00:00 EDT Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV DrugsCondition: HIV InfectionsInterventions: Drug: Atazanavir; Drug: Nelfinavir mesylate; Drug: Stavudine; Drug: Didanosine Sponsor: Bristol-Myers Squibb Completed Fri, 31 Aug 2001 12:00:00 EDT
The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive SubjectsCondition: HIV InfectionsInterventions: Drug: nevirapine; Drug: atazanavir/ritonavir Sponsors: Imperial College London; Boehringer Ingelheim Completed Fri, 05 Oct 2007 12:00:00 EDT Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/TenofovirCondition: HIV InfectionsInterventions: Drug: Atazanavir+Ritonavir+Tenofovir; Drug: Atazanavir+Ritonavir+Tenofovir+Famotidine Sponsor: Bristol-Myers Squibb Completed Thu, 17 Aug 2006 12:00:00 EDT A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy VolunteersCondition: Healthy VolunteerInterventions: Drug: RO5093151; Drug: atazanavir; Drug: ketoconazole; Drug: rifampicin; Drug: ritonavir Sponsor: Hoffmann-La Roche Completed Fri, 04 May 2012 12:00:00 EDT Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and KivexaConditions: HIV; Impaired CognitionInterventions: Drug: standard care; Drug: novel treatment Sponsors: Imperial College London; Pfizer Completed Tue, 07 Jun 2011 12:00:00 EDT Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected WomenCondition: HIV InfectedIntervention: Drug: Tenofovir, Emtricitabine, Atazanavir, Ritonavir Sponsors: University of Alabama at Birmingham; National Institute of Allergy and Infectious Diseases (NIAID) Withdrawn Thu, 14 Jul 2011 12:00:00 EDT Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/RitonavirConditions: HIV; DyslipidemiaInterventions: Drug: pitavastatin; Drug: placebo Sponsor: Ramathibodi Hospital Completed Wed, 13 May 2015 12:00:00 EDT Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in EuropeCondition: HIV InfectionIntervention: Sponsors: Bristol-Myers Squibb; PENTA Foundation Completed Fri, 08 Jul 2011 12:00:00 EDT HIV Antiretroviral Drugs and MetabolismCondition: HIV InfectionsIntervention: Drug: ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, efavirenz Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Unknown status Wed, 05 Sep 2007 12:00:00 EDT Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric ParticipantsConditions: Acquired Immune Deficiency Syndrome (AIDS); HIV InfectionsInterventions: Drug: ATV; Drug: DRV; Drug: Cobicistat; Drug: BR Sponsor: Gilead Sciences Recruiting Fri, 20 Dec 2013 12:00:00 EST A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation: the ASK-500 StudyCondition: HIV InfectionsInterventions: Drug: saquinavir 500 formulation; Drug: cross-over arm Sponsors: Kirby Institute; Hoffmann-La Roche Completed Mon, 19 Sep 2005 12:00:00 EDT
Drug Interaction Study With Proton Pump InhibitorCondition: HIV InfectionsInterventions: Drug: Atazanavir; Drug: Atazanavir/Ritonavir; Drug: Atazanavir/Ritonavir+Omeprazole Sponsor: Bristol-Myers Squibb Completed Thu, 27 Jul 2006 12:00:00 EDT Impact of Hyperbilirubinemia Among HIV Patients Treated With AtazanavirCondition: HIV/AIDSIntervention: Sponsor: Bristol-Myers Squibb Completed Wed, 26 Aug 2015 12:00:00 EDT Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin MetabolismCondition: HIV InfectionsIntervention: Drug: Atazanavir/Ritonavir/Lopinavir/ritonavir Sponsor: Bristol-Myers Squibb Completed Fri, 26 Aug 2005 12:00:00 EDT Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive AdultsCondition: HIV InfectionsInterventions: Drug: Abacavir/Lamivudine; Drug: Atazanavir; Drug: Efavirenz; Drug: Emtricitabine/Tenofovir disoproxil fumarate; Drug: Ritonavir; Drug: Abacavir/Lamivudine placebo; Drug: Emtricitabine/Tenofovir disoproxil fumarate placebo Sponsors: AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID) Completed Tue, 12 Jul 2005 12:00:00 EDT Long-term Atazanavir Experience in a High HIV Caseload Primary Care Practice in Sydney, AustraliaCondition: HIVIntervention: Sponsors: Holdsworth House Medical Practice; Bristol-Myers Squibb Completed Thu, 12 Sep 2013 12:00:00 EDT Antiviral Agents Against COVID-19 InfectionCondition: COVID-19Interventions: Drug: Atazanavir; Drug: Daclatasvir 60 mg; Drug: Sofusbuvir + Daclastavir 60 mg; Drug: Placebo Atazanavir; Drug: Placebo Daclatasvir 60 mg; Drug: Placebo Sofusbuvir + Daclatasvir 60 mg Sponsor: Hospital do Coracao Recruiting Mon, 13 Jul 2020 12:00:00 EDT Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDSCondition: HIV/AIDSInterventions: Drug: Darunavir; Drug: ART with 2 NRTIs plus LPV/r (or ATV/r) Sponsors: University of Liverpool; Janssen Pharmaceutica; Chantal Biya International Reference Centre for Research on Prevention and Management of HIV/AIDS; Yaounde Central Hospital Completed Wed, 04 Jun 2014 12:00:00 EDT Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r)Condition: HIV InfectionsInterventions: Procedure: Early Initiation of Highly Active Anti-Retroviral Therapy; Procedure: Standard Care Sponsors: University of North Carolina, Chapel Hill; National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH); International Maternal Pediatric Adolescent AIDS Clinical Trials Group Completed Tue, 26 Jun 2007 12:00:00 EDT A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)Conditions: Infection, Human Immunodeficiency Virus; HIV InfectionsInterventions: Drug: Dolutegravir/abacavir/lamivudine FDC; Drug: Atazanavir; Drug: Ritonavir; Drug: Tenofovir/emtricitabine FDC Sponsors: ViiV Healthcare; GlaxoSmithKline Active, not recruiting Mon, 29 Jul 2013 12:00:00 EDT Evaluation of Atazanavir Substitution Intervention (EASI) StudyCondition: HIV InfectionsIntervention: Sponsor: University of British Columbia Completed Wed, 02 Nov 2005 12:00:00 EST
ANRS 12372 MODERATO StudyCondition: HIV-1-infectionInterventions: Drug: dolutegravir; Drug: atazanavir boosted with ritonavir; Drug: tenofovir + lamivudine +efavirenz; Drug: Lamivudine Sponsors: ANRS, Emerging Infectious Diseases; Mylan Laboratories Recruiting Wed, 17 Jul 2019 12:00:00 EDT Pharmacokinetic Effect of Evotaz/Microgynon Co-administrationCondition: HIVInterventions: Drug: Microgynon 30®; Drug: Evotaz® Sponsors: St Stephens Aids Trust; Bristol-Myers Squibb Terminated Thu, 03 Mar 2016 12:00:00 EST Low Dose Atazanavir/r Versus Standard Dose Atazanavir/r (LASA)Condition: HIV InfectionsIntervention: Drug: ATV/r Sponsors: The HIV Netherlands Australia Thailand Research Collaboration; Kirby Institute; National Health Security Office, Thailand Completed Fri, 09 Jul 2010 12:00:00 EDT Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected AdultsCondition: HIV-1 InfectionInterventions: Drug: RTV; Drug: ATV; Drug: DRV; Drug: COBI; Drug: ATV/co; Drug: DRV/co; Drug: FTC/TDF; Drug: ABC/3TC; Drug: B/F/TAF Sponsor: Gilead Sciences Completed Wed, 11 Nov 2015 12:00:00 EST A Study on Antiretroviral Therapy (ART) Naïve Patients On Different Regimens to Treat Hiv (NORTHIV)Condition: HIVInterventions: Drug: Lopinavir ritonavir; Drug: Atazanavir ritonavir; Drug: Efavirenz Sponsor: Göteborg University Completed Mon, 03 Oct 2011 12:00:00 EDT Study to Evaluate a HIV Drug for the Treatment of HIV InfectionConditions: Infection, Human Immunodeficiency Virus; HIV InfectionsInterventions: Drug: BMS-955176; Drug: Placebo matching with BMS-955176; Drug: Atazanavir; Drug: Ritonavir; Drug: Tenofovir; Drug: Emtricitabine Sponsors: ViiV Healthcare; GlaxoSmithKline Completed Mon, 04 Mar 2013 12:00:00 EST The Effect of Protease Inhibitors on the Pharmacokinetics of Oral Norethindrone ContraceptionConditions: Pregnancy; HIV; AIDSIntervention: Drug: Norethindrone acetate Sponsors: University of Southern California; Society of Family Planning Completed Fri, 17 Aug 2012 12:00:00 EDT Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced AdultsCondition: HIV InfectionsInterventions: Drug: BMS-955176; Drug: Atazanavir (ATV); Drug: Ritonavir (RTV); Drug: Dolutegravir (DTG); Drug: Tenofovir (TDF) Sponsors: ViiV Healthcare; GlaxoSmithKline Terminated Wed, 11 Mar 2015 12:00:00 EDT Atazanavir/Ritonavir and Zinc Pharmacokinetic StudyCondition: HIV InfectionInterventions: Drug: 1 Solvazinc tablet, day 2 to day 15; Drug: 1 Solvazinc tablet, day 15 to day 28 Sponsor: St Stephens Aids Trust Completed Mon, 21 Nov 2011 12:00:00 EST Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral TherapyCondition: HIV InfectionsIntervention: Drug: Addition of raltegravir 800 mg QD to HAART Sponsors: Germans Trias i Pujol Hospital; Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia Completed Fri, 18 Jul 2008 12:00:00 EDT
Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected AdultsCondition: HIV-1 InfectionInterventions: Drug: STB; Drug: TVD; Drug: ATR; Drug: RTV; Drug: ATV; Drug: ABC/3TC; Drug: Iohexol Sponsor: Gilead Sciences Completed Tue, 23 Sep 2014 12:00:00 EDT PK of Once Daily ART Containing Tenofovir and Atazanavir/RitonavirCondition: HIV InfectionsIntervention: Procedure: blood draw Sponsors: University of North Carolina, Chapel Hill; National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH); National Institute on Alcohol Abuse and Alcoholism (NIAAA) Completed Mon, 09 Jan 2006 12:00:00 EST Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy WomenCondition: HealthyInterventions: Drug: tenofovir; Drug: emtricitabine; Drug: atazanavir; Drug: ritonavir Sponsors: University of Alabama at Birmingham; National Institute of Allergy and Infectious Diseases (NIAID) Completed Thu, 26 Mar 2009 12:00:00 EDT Early and Intermittent Antiretroviral Therapy in Naive HIV Infected AdultsCondition: HIV InfectionsIntervention: Drug: Structured treatment interruption Sponsor: ANRS, Emerging Infectious Diseases Completed Fri, 09 Jan 2009 12:00:00 EST Disulfiram Interactions With HIV Medications: Clinical ImplicationsConditions: HIV Infections; Drug AbuseInterventions: Drug: Disulfiram; Drug: Disulfiram + Efavirenz; Drug: Disulfiram + Atazanavir; Drug: Disulfiram + Ritonavir Sponsors: University of California, San Francisco; National Institute on Drug Abuse (NIDA) Completed Wed, 08 Apr 2009 12:00:00 EDT Comparative Study of Three NNRTI-Sparing HAART RegimensCondition: HIV InfectionInterventions: Drug: Emtricitabine/tenofovir disoproxil fumarate; Drug: Raltegravir; Drug: Darunavir; Drug: Ritonavir; Drug: Atazanavir Sponsors: AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Bristol-Myers Squibb; Gilead Sciences; Merck Sharp & Dohme Corp.; Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA Completed Fri, 19 Dec 2008 12:00:00 EST Pharmacogenomic of Atazanavir/Efavirenz (ATV/EFV)Condition: HIV InfectionsIntervention: Sponsors: The HIV Netherlands Australia Thailand Research Collaboration; Chulalongkorn University; Kirby Institute; Radboud University; South East Asia Research Collaboration with Hawaii Completed Mon, 07 Jun 2010 12:00:00 EDT Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsConditions: HIV; HIV InfectionsInterventions: Drug: Stribild; Drug: ATV; Drug: Ritonavir; Drug: FTC/TDF; Drug: Stribild Placebo; Drug: ATV Placebo; Drug: RTV Placebo; Drug: FTC/TDF Placebo Sponsor: Gilead Sciences Completed Tue, 20 Apr 2010 12:00:00 EDT HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based RegimenCondition: HIV-1Interventions: Drug: Dolutegravir; Drug: PI; Drug: 2 NRTI Sponsors: Hospital Universitari Vall d'Hebron Research Institute; University Hospital, Ghent; IrsiCaixa Completed Fri, 31 Jul 2015 12:00:00 EDT Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular ParametersCondition: HIV InfectionInterventions: Drug: Emtricitabine/tenofovir disoproxil fumarate; Drug: Ritonavir; Drug: Atazanavir; Drug: Raltegravir; Drug: Darunavir Sponsors: AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID) Completed Thu, 26 Feb 2009 12:00:00 EST
Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir Administered With RIfampicin to HIV Positive Adults on sEcond-line ART Regimen With Suppressed HIV-1 Viral LoadConditions: HIV/AIDS; TuberculosisIntervention: Drug: Dose escalation Sponsors: University of Liverpool; European and Developing Countries Clinical Trials Partnership (Funder); Joint Clinical Research Centre, Kampala, Uganda; University of Cape Town, Cape Town, South Africa; Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda; University of Turin, Turin, Italy Recruiting Wed, 09 Oct 2019 12:00:00 EDT Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected SubjectsCondition: HIV InfectionIntervention: Drug: LPV/RTV + 2NRTIs Sponsor: Bristol-Myers Squibb Completed Tue, 16 Nov 2004 12:00:00 EST Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life SettingCondition: HIVIntervention: Sponsors: Bristol-Myers Squibb; PharmaNet Completed Sun, 07 Nov 2010 12:00:00 EDT Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and AdolescentsCondition: HIV InfectionsInterventions: Drug: ATV; Drug: Ritonavir Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); International Maternal Pediatric Adolescent AIDS Clinical Trials Group Completed Fri, 31 Aug 2001 12:00:00 EDT Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/MclCondition: HIV InfectionsInterventions: Drug: tenofovir + emtricitabine + efavirenz; Drug: tenofovir + emtricitabine + lopinavir-ritonavir; Drug: tenofovir + emtricitabine + atazanavir-ritonavir Sponsor: Juan A. Arnaiz Completed Thu, 20 Sep 2007 12:00:00 EDT Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV PatientsCondition: HIV InfectionsInterventions: Drug: Atazanavir; Drug: Stavudine; Drug: Didanosine Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Bristol-Myers Squibb Completed Fri, 31 Aug 2001 12:00:00 EDT PK TDF in Thai HIV-infected ChildrenCondition: HIVInterventions: Drug: TDF (Tenofovir); Drug: Efavirenz; Drug: lopinavir/ritonavir, atazanavir/ritonavir Sponsors: The HIV Netherlands Australia Thailand Research Collaboration; Chulalongkorn University; Khon Kaen University Completed Tue, 31 Mar 2015 12:00:00 EDT ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial RegimensCondition: Human Immunodeficiency Virus (HIV)Interventions: Drug: Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz); Drug: Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV); Drug: Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC) Sponsors: Kirby Institute; The University of New South Wales Completed Fri, 09 Jun 2006 12:00:00 EDT Effect of Different Boosting Agents on Pharmacokinetics of BILR 355 BS Dissolved in Polyethylene Glycol 400 (PEG 400) in Healthy Male VolunteersCondition: HealthyInterventions: Drug: BILR 355 BS; Other: Grapefruit juice; Drug: Nelfinavir; Drug: Atazanavir; Drug: Ritonavir Sponsor: Boehringer Ingelheim Completed Mon, 06 Oct 2014 12:00:00 EDT Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)Condition: HIV InfectionsInterventions: Drug: Vicriviroc; Drug: emtricitabine and tenofovir disoproxil fumarate Sponsor: Merck Sharp & Dohme Corp. Completed Tue, 30 Oct 2007 12:00:00 EDT
Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected SubjectsCondition: HIV InfectionIntervention: Drug: Aprepitant Sponsor: University of Pennsylvania Completed Tue, 03 Jun 2014 12:00:00 EDT Clinical Trial of CNS-targeted HAART (CIT2)Condition: HIV InfectionsIntervention: Drug: FDA Approved Antiretroviral Therapy (see list below) Sponsors: University of California, San Diego; National Institutes of Health (NIH); National Institute of Mental Health (NIMH) Completed Wed, 27 Feb 2008 12:00:00 EST Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive WomenConditions: Acquired Immunodeficiency Syndrome; HIV InfectionsInterventions: Drug: E/C/F/TDF; Drug: ATV; Drug: RTV; Drug: FTC/TDF; Drug: E/C/F/TDF Placebo; Drug: ATV Placebo; Drug: RTV Placebo; Drug: FTC/TDF Placebo; Drug: E/C/F/TAF Sponsor: Gilead Sciences Completed Fri, 12 Oct 2012 12:00:00 EDT Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIVCondition: HIV InfectionsInterventions: Drug: Nevirapine; Drug: Efavirenz; Drug: Indinavir/ritonavir; Drug: Nelfinavir; Drug: Saquinavir/ritonavir; Drug: Lopinavir/ritonavir; Drug: Atazanavir; Drug: Atazanavir/ritonavir; Drug: Fos-amprenavir/ritonavir; Drug: Tipranavir/ ritonavir; Drug: Darunavir/ritonavir Sponsors: Germans Trias i Pujol Hospital; Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia Completed Tue, 28 Mar 2006 12:00:00 EST Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected WomenCondition: HIV-1 InfectionInterventions: Drug: E/C/F/TAF; Drug: E/C/F/TDF; Drug: ATV; Drug: RTV; Drug: FTC/TDF; Drug: B/F/TAF Sponsor: Gilead Sciences Completed Tue, 12 Jan 2016 12:00:00 EST Influence of Antiretroviral Regimen on Immune Reconstitution in the Female Genital TractConditions: Women's Health; HIV Infection; Genital Diseases, FemaleIntervention: Sponsor: University of Colorado, Denver Completed Fri, 21 Oct 2011 12:00:00 EDT Population Pharmacokinetics of Antiretroviral in ChildrenCondition: Minor Patient Treated by One or More Antiretroviral and for Which a Blood Test Has Been PerformedInterventions: Biological: Dolutegravir; Biological: Raltegravir; Biological: Rilpivirine; Biological: Nevirapine; Biological: Atazanavir; Biological: Darunavir; Biological: Ritonavir Sponsor: Assistance Publique - Hôpitaux de Paris Recruiting Wed, 21 Jun 2017 12:00:00 EDT Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TCCondition: HIVInterventions: Drug: Atazanavir; Drug: Ritonavir; Drug: Lamivudine; Drug: Tenofovir/Emtricitabine Sponsor: Bristol-Myers Squibb Terminated Fri, 15 Jun 2012 12:00:00 EDT Antiretroviral Drug Interaction Study in Volunteers With HIVConditions: HIV; PCP; ToxoplasmosisInterventions: Drug: Atovaquone 750 mg twice daily; Drug: Atovaquone 1500 mg twice daily Sponsor: National Institutes of Health Clinical Center (CC) Completed Thu, 24 Nov 2011 12:00:00 EST Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)Condition: HIV InfectionsInterventions: Drug: Raltegravir (MK-0518); Drug: Nevirapine; Drug: Lamivudine; Drug: Tenofovir; Drug: Emtricitabine; Drug: Lopinavir; Drug: Ritonavir; Drug: Atazanavir; Drug: Darunavir Sponsor: Merck Sharp & Dohme Corp. Terminated Thu, 17 Apr 2014 12:00:00 EDT
Unboosted Atazanavir as Initial ART Therapy in ChinaCondition: Antiretroviral TherapyIntervention: Sponsors: National Center for AIDS/STD Control and Prevention, China CDC; BMS company Completed Tue, 25 Oct 2011 12:00:00 EDT Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV PatientsConditions: HIV Infections; Lipodystrophy; Wasting DiseaseInterventions: Drug: Abacavir sulfate; Drug: Atazanavir/Ritonavir; Drug: Lopinavir/Ritonavir; Drug: Nevirapine Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Completed Fri, 21 Dec 2001 12:00:00 EST Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After PregnancyCondition: HIV InfectionsInterventions: Drug: atazanavir/cobicistat; Drug: darunavir/ritonavir; Drug: darunavir/cobicistat; Drug: etravirine; Drug: elvitegravir/cobicistat; Drug: dolutegravir; Drug: tenofovir alafenamide fumarate (TAF); Drug: TAF/cobicistat; Drug: TAF/ritonavir; Drug: efavirenz; Drug: lopinavir/ritonavir; Drug: nevirapine; Drug: rifampicin; Drug: ethambutol; Drug: isoniazid; Drug: pyrazinamide; Drug: kanamycin; Drug: amikacin; Drug: capreomycin; Drug: moxifloxacin; Drug: levofloxacin; Drug: ofloxacin; Drug: ethionamide/prothionamide; Drug: terizidone/cycloserine; Drug: para-aminosalicylic acid (PAS); Drug: high dose isoniazid (INH); Drug: bedaquiline; Drug: clofazamine; Drug: delamanid; Drug: linezolid; Drug: pretomanid; Drug: atazanavir/ritonavir/tenofovir; Drug: ethinyl estradiol oral contraceptive; Drug: etonogestrel implant Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Completed Thu, 01 Aug 2002 12:00:00 EDT Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal ImpairmentConditions: Acquired Immunodeficiency Syndrome; HIV InfectionsInterventions: Drug: E/C/F/TDF; Drug: COBI; Drug: ATV; Drug: DRV; Drug: NRTI Sponsor: Gilead Sciences Completed Wed, 01 Jun 2011 12:00:00 EDT Sex, Aging and Antiretroviral PharmacokineticsCondition: HIV InfectionsIntervention: Drug: ARV regimen chosen by treating physician Sponsors: Kristine Patterson, MD; National Institute of Allergy and Infectious Diseases (NIAID) Completed Thu, 24 Apr 2008 12:00:00 EDT Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited SettingsCondition: HIV InfectionsInterventions: Drug: Atazanavir; Drug: Didanosine (enteric-coated); Drug: Efavirenz; Drug: Emtricitabine; Drug: Emtricitabine/Tenofovir disoproxil fumarate; Drug: Lamivudine/Zidovudine Sponsors: AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID) Completed Tue, 08 Jun 2004 12:00:00 EDT Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the GutCondition: HIV InfectionsInterventions: Drug: raltegravir; Drug: Study NNRTI; Drug: Study PI Sponsor: University of California, San Francisco Completed Tue, 21 Apr 2009 12:00:00 EDT Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.Conditions: Hepatitis C; HIVInterventions: Drug: SOF; Drug: EFV/FTC/TDF; Drug: EFV; Drug: ZDV/3TC; Drug: ATV; Drug: Ritonavir; Drug: FTC/TDF; Drug: DRV; Drug: RAL; Drug: PEG; Drug: RBV Sponsor: Gilead Sciences Completed Thu, 29 Mar 2012 12:00:00 EDT Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral TherapyConditions: Ebola; HIV/AIDSIntervention: Drug: Remdesivir Sponsors: Makerere University; University of Liverpool; European and Developing Countries Clinical Trials Partnership (EDCTP); University of Turin, Italy Completed Wed, 13 May 2020 12:00:00 EDT A Study of Prevalence of the I50L Mutation When ATV Treated Patients Fail the RegimenCondition: HIV InfectionsIntervention: Sponsor: Bristol-Myers Squibb Completed Fri, 26 Aug 2005 12:00:00 EDT
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) InfectionsCondition: Infection, Human Immunodeficiency VirusInterventions: Drug: BMS-663068 400 mg; Drug: BMS-663068 800 mg; Drug: BMS-663068 600 mg; Drug: BMS-663068 1200 mg; Drug: Raltegravir 400 mg; Drug: Tenofovir 300 mg; Drug: Ritonavir 100 mg; Drug: Atazanavir 300 mg Sponsor: ViiV Healthcare Completed Wed, 29 Jun 2011 12:00:00 EDT Antiretroviral Therapy and Extreme WeightCondition: HIV InfectionIntervention: Sponsor: Hopital Lariboisière Completed Wed, 06 Mar 2013 12:00:00 EST Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)Condition: HIV InfectionsInterventions: Drug: Fosamprenavir; Drug: Saquinavir Sponsors: French National Agency for Research on AIDS and Viral Hepatitis; Bristol-Myers Squibb; GlaxoSmithKline; Hoffmann-La Roche Completed Fri, 22 Jul 2005 12:00:00 EDT Preventing Sexual Transmission of HIV With Anti-HIV DrugsCondition: HIV InfectionsInterventions: Drug: Atazanavir; Drug: Didanosine; Drug: Efavirenz; Drug: Emtricitabine/Tenofovir disoproxil fumarate; Drug: Lamivudine; Drug: Lopinavir/Ritonavir; Drug: Nevirapine; Drug: Stavudine; Drug: Tenofovir disoproxil fumarate; Drug: Zidovudine/Lamivudine Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); HIV Prevention Trials Network Completed Wed, 17 Dec 2003 12:00:00 EST IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young AdultsCondition: HIV InfectionsInterventions: Drug: Raltegravir (RAL); Drug: Atazanavir (ATV); Drug: Ritonavir (RTV); Drug: Tenofovir (TDF); Drug: Etravirine (ETV); Drug: Darunavir (DRV); Drug: Maraviroc (MVC); Drug: Lopinavir/ritonavir (LPV/r) Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID) Completed Wed, 16 Sep 2009 12:00:00 EDT Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected ParticipantsCondition: Human Immunodeficiency Virus Type 1Interventions: Drug: D/C/F/TAF; Drug: Boosted Protease Inhibitor (bPI); Drug: FTC/TDF Sponsor: Janssen R&D Ireland Completed Tue, 21 Oct 2014 12:00:00 EDT Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)Condition: HIV-1 InfectionInterventions: Drug: Doravirine, Tenofovir, Lamivudine; Drug: Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor; Drug: Baseline regimen of cobicistat-boosted elvitegravir; Drug: Baseline regimen of a non-nucleoside reverse transcriptase inhibitor; Drug: Baseline regimen of two nucleoside reverse transcriptase inhibitors Sponsor: Merck Sharp & Dohme Corp. Active, not recruiting Tue, 24 Mar 2015 12:00:00 EDT Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV InfectionCondition: HIV InfectionsInterventions: Drug: Abacavir sulfate, Lamivudine and Zidovudine; Drug: Atazanavir; Drug: Lamivudine/Zidovudine; Drug: Abacavir sulfate; Drug: Efavirenz; Drug: Nevirapine; Drug: Lamivudine; Drug: Stavudine; Drug: Zidovudine; Drug: Didanosine Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Completed Fri, 31 Aug 2001 12:00:00 EDT Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive ParticipantsConditions: HIV; HIV InfectionsInterventions: Drug: E/C/F/TAF; Drug: E/C/F/TDF; Drug: EFV/FTC/TDF; Drug: RTV; Drug: ATV; Drug: FTC/TDF; Drug: COBI Sponsor: Gilead Sciences Completed Thu, 21 Mar 2013 12:00:00 EDT Comparative Tolerability of Protease InhibitorsCondition: HIVIntervention: Sponsor: Bristol-Myers Squibb Completed Wed, 12 Oct 2011 12:00:00 EDT
Antiretroviral Localization in Gut-Associated Lymphoid Tissue and Lower Female Genital Tract Tissue of HIV+ SubjectsCondition: HIVInterventions: Procedure: Blood plasma collection; Procedure: Cervical and Vaginal Biopsy; Procedure: Colonoscopy with Ileal and Rectal Biopsy Sponsor: University of North Carolina, Chapel Hill Terminated Tue, 29 Dec 2015 12:00:00 EST Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and PostpartumConditions: HIV Infections; TuberculosisInterventions: Drug: Bictegravir (BIC); Drug: Tenofovir alafenamide (TAF); Drug: Cabotegravir (CAB); Drug: Dolutegravir (DTG); Drug: Atazanavir/ritonavir (ATV/r); Drug: Darunavir/ritonavir (DRV/r); Drug: Lopinavir/ritonavir (LPV/r); Drug: Cobicistat; Drug: Ritonavir; Drug: First-Line TB Treatment; Drug: Second-Line TB Treatment; Drug: Doravirine (DOR) Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Mental Health (NIMH); Gilead Sciences; ViiV Healthcare; Merck Sharp & Dohme Corp. Recruiting Wed, 19 Aug 2020 12:00:00 EDT Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ARTCondition: HIV-1 InfectionInterventions: Device: Nuvaring; Drug: EFV; Drug: ATV/r; Drug: TDF; Drug: NRTIs Sponsors: AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID) Completed Fri, 19 Jul 2013 12:00:00 EDT Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected ChildrenCondition: HIV InfectionsInterventions: Drug: Atazanavir; Drug: Darunavir; Drug: Efavirenz; Drug: Nevirapine; Drug: Ritonavir; Drug: Tenofovir disoproxil fumarate; Procedure: Pharmacokinetic Study Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Completed Thu, 01 Dec 2005 12:00:00 EST Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple TherapyCondition: HIVInterventions: Drug: triple therapy; Drug: dual therapy Sponsors: University Hospital, Tours; HOSPITAL, ORLEANS; Poitiers University Hospital; Centre Hospitalier de La Rochelle; HOSPITAL, SAINTES; HOSPITAL, FOCH; HOSPITAL, CAEN; Henri Mondor University Hospital; HOSPITAL, HOTEL DIEU; HOSPITAL, CHARTRES; HOSPITAL, SAINT LOUIS; Tourcoing Hospital; Central Hospital, NIORT; Tenon Hospital, Paris; Central Hospital, Nancy, France; University Hospital, Rouen Completed Thu, 27 Nov 2014 12:00:00 EST Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life ConditionsConditions: Human Immunodeficiency Virus; Hepatitis B, Chronic; Hepatitis C, ChronicIntervention: Drug: antiretroviral drugs Sponsors: Valme University Hospital; Hospital Universitario Virgen de la Victoria; Hospital Universitario Reina Sofia de Cordoba; Hospital Torrecárdenas; Hospital de la Línea de la Concepción; Hospital Poniente; Hospital Universitario Virgen Macarena; Complejo Hospitalario de Especialidades Juan Ramón Jimenez Completed Fri, 26 Jul 2013 12:00:00 EDT A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)Condition: Hepatitis CInterventions: Drug: Telaprevir; Drug: Ribavirin; Biological: Pegylated Interferon Alfa-2a; Drug: Highly Active Antiretroviral Therapy (HAART) Sponsor: Vertex Pharmaceuticals Incorporated Terminated Tue, 08 Nov 2011 12:00:00 EST Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infectionConditions: HIV; Hepatitis C; Liver FibrosisInterventions: Drug: Raltegravir; Drug: Ritonavir-boosted protease inhibitor Sponsors: McGill University Health Centre/Research Institute of the McGill University Health Centre; Merck Sharp & Dohme Corp.; CIHR Canadian HIV Trials Network Completed Mon, 01 Nov 2010 12:00:00 EDT IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and AdolescentsConditions: ADHD; HIVIntervention: Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group Completed Tue, 02 Nov 2010 12:00:00 EDT Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 InfectionCondition: HIV InfectionsInterventions: Drug: EVG; Drug: RTV; Drug: ARV regimen Sponsor: Gilead Sciences Completed Thu, 08 Mar 2007 12:00:00 EST
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected PatientsCondition: HIV InfectionsIntervention: Drug: Treatment discontinuation Sponsors: ANRS, Emerging Infectious Diseases; IMEA Leon M'Ba Foundation; Unit 1136 INSERM, Faculty of medecine, University Pierre and Marie Curie Unknown status Tue, 22 Aug 2017 12:00:00 EDT IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum WomenCondition: HIV InfectionIntervention: Drug: Highly active antiretroviral therapy (HAART) Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Completed Mon, 10 Aug 2009 12:00:00 EDT MARCH Vascular Endothelium SubstudyCondition: Cardiovascular DiseaseInterventions: Drug: NRTI + PI; Drug: maraviroc + PI; Drug: maraviroc + NRTI Sponsor: Kirby Institute Completed Thu, 26 Apr 2012 12:00:00 EDT MARCH Renal SubstudyConditions: Proteinuria; HIVInterventions: Drug: arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors; Drug: Arm 2 boosted protease inhibitors and maraviroc; Drug: Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc Sponsor: Kirby Institute Completed Wed, 11 Jul 2012 12:00:00 EDT 4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV PatientsCondition: HIV-1 InfectionIntervention: Drug: Four consecutive days on treatment and 3 days off Sponsor: ANRS, Emerging Infectious Diseases Completed Fri, 06 Jun 2014 12:00:00 EDT MARCH Central Nervous System SubstudyCondition: HIV-1 InfectionInterventions: Drug: Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors; Drug: Arm 2 Maraviroc and Protease Inhibitors; Drug: Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors Sponsor: Kirby Institute Completed Wed, 11 Jul 2012 12:00:00 EDT Treatment De-Intensification and Residual HIV-1 in YouthConditions: HIV-1; HIV InfectionsIntervention: Other: Blood draw Sponsors: University of North Carolina, Chapel Hill; National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH) Completed Tue, 24 Mar 2009 12:00:00 EDT TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and AdolescentsCondition: HIV-1Interventions: Drug: Etravirine (TMC125); Drug: Optimized background regimen (OBR) Sponsor: Tibotec Pharmaceuticals, Ireland Completed Thu, 24 Apr 2008 12:00:00 EDT Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)Condition: HIV InfectionsInterventions: Drug: DTG/3TC FDC; Drug: CAR Sponsors: ViiV Healthcare; GlaxoSmithKline; PPD Active, not recruiting Tue, 16 Jul 2019 12:00:00 EDT Telaprevir Open-Label Study in Co-Infected PatientsCondition: Hepatitis C, ChronicIntervention: Drug: Telaprevir Sponsor: Janssen-Cilag International NV Completed Wed, 28 Dec 2011 12:00:00 EST
Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed AdultsConditions: HIV-1-infection; Antiretroviral TherapyInterventions: Drug: Continuation of boosted PI; Drug: B/F/TAF Sponsors: Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic; Brigham and Women's Hospital; Harvard Medical School; Analysis Group, Inc.; Weill Medical College of Cornell University Not yet recruiting Tue, 17 Mar 2020 12:00:00 EDT Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric ParticipantsConditions: Acquired Immune Deficiency Syndrome (AIDS); HIV InfectionsInterventions: Drug: EVG; Drug: Background regimen Sponsor: Gilead Sciences Terminated Thu, 15 Aug 2013 12:00:00 EDT Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus RaltegravirCondition: HIV InfectionInterventions: Drug: Elvitegravir; Drug: Raltegravir; Drug: EVG placebo; Drug: RAL placebo; Drug: Background regimen Sponsor: Gilead Sciences Completed Wed, 02 Jul 2008 12:00:00 EDT Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184ICondition: HIV-1 InfectionIntervention: Drug: E/C/F/TAF Sponsor: Gilead Sciences Completed Thu, 26 Nov 2015 12:00:00 EST Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV SubjectsConditions: HIV; HIV InfectionsInterventions: Drug: maraviroc; Drug: control group Sponsor: Germans Trias i Pujol Hospital Completed Wed, 26 Aug 2009 12:00:00 EDT A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic ProgramCondition: Adverse Drug ReactionIntervention: Other: Pharmacogenetic Intervention Arm (pharmacogenetic testing) Sponsors: Indiana University; National Human Genome Research Institute (NHGRI) Completed Fri, 21 Nov 2014 12:00:00 EST Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)Condition: Human Immunodeficiency VirusIntervention: Sponsor: Merck Sharp & Dohme Corp. Terminated Wed, 20 Mar 2013 12:00:00 EDT Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2- Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing RegimenCondition: HIV-1Interventions: Drug: F/TAF; Drug: 3rd ARV agent; Drug: Boosted PIs Sponsor: Gilead Sciences Active, not recruiting Thu, 06 Nov 2014 12:00:00 EST Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin RegimenConditions: Hepatitis C, Chronic; HIV InfectionInterventions: Drug: Telaprevir; Biological: pegIFN alfa-2a; Drug: Ribavirin Sponsors: ANRS, Emerging Infectious Diseases; Janssen-Cilag Ltd. Completed Mon, 11 Apr 2011 12:00:00 EDT Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American ParticipantsCondition: HIV-1 InfectionInterventions: Drug: B/F/TAF; Drug: NRTIs; Drug: Third Agent Sponsor: Gilead Sciences Completed Wed, 15 Aug 2018 12:00:00 EDT
Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected AdultsCondition: HIV-1 InfectionInterventions: Drug: E/C/F/TAF; Drug: ABC/3TC; Drug: Third Antiretroviral Agent Sponsor: Gilead Sciences Completed Tue, 17 Nov 2015 12:00:00 EST Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected PatientsConditions: Acquired Immunodeficiency Syndrome; HIV InfectionsInterventions: Drug: PI; Drug: RTV; Drug: FTC/TDF; Drug: Stribild Sponsor: Gilead Sciences Completed Mon, 21 Nov 2011 12:00:00 EST Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DFCondition: HIV-1 InfectionInterventions: Drug: FTC/RPV/TDF; Drug: PI; Drug: RTV; Drug: NRTIs Sponsor: Gilead Sciences Completed Fri, 03 Dec 2010 12:00:00 EST A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 CoinfectionConditions: Hepatitis C Virus Infection; Human Immunodeficiency Virus Infection; Chronic Hepatitis C; Compensated Cirrhosis and Non-cirrhoticsInterventions: Drug: ABT-450/r/ABT-267; Drug: ABT-333; Drug: ribavirin Sponsor: AbbVie Completed Wed, 11 Sep 2013 12:00:00 EDT Kidney Stone Risk Factors in Patients Infected With HIVConditions: Nephrolithiasis; HIVIntervention: Sponsor: Corinne Isnard Bagnis Unknown status Fri, 29 May 2015 12:00:00 EDT Kuwa Free! - Live Free!Conditions: HIV Infections; Contraception; Drug-drug InteractionInterventions: Drug: Cabotegravir/ Rilpivirine; Drug: Etonogestrel (ETG) implant; Drug: Intramuscular depo-medroxyprogesterone acetate (IM DMPA); Drug: Levonorgestrel; Drug: NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens Sponsors: University of Washington; Moi Teaching and Referral Hospital; Indiana University; University of Nebraska; National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting Thu, 16 Sep 2021 12:00:00 EDT Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDFCondition: HIV-1 InfectionInterventions: Drug: FTC/TDF; Drug: F/TAF; Drug: Allowed third antiretroviral agent; Drug: FTC/TDF Placebo; Drug: F/TAF Placebo Sponsor: Gilead Sciences Completed Thu, 24 Apr 2014 12:00:00 EDT Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TCCondition: HIV-1 InfectionInterventions: Drug: F/TAF; Drug: ABC/3TC; Drug: ABC/3TC Placebo; Drug: F/TAF Placebo; Drug: 3rd ARV agent Sponsor: Gilead Sciences Completed Thu, 11 Jun 2015 12:00:00 EDT Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected AdultsConditions: Infection, Human Immunodeficiency Virus; HIV InfectionsInterventions: Drug: Cabotegravir (CAB) tablet; Drug: Rilpivirine (RPV) tablet; Drug: Cabotegravir - Injectable Suspension (CAB LA); Drug: Rilpivirine - Injectable Suspension (RPV LA); Drug: 2 NRTIs plus an INI, NNRTI, or PI Sponsors: ViiV Healthcare; Janssen Pharmaceuticals; GlaxoSmithKline Active, not recruiting Tue, 01 Nov 2016 12:00:00 EDT Interaction With HIV Antiretroviral AgentsCondition: HIV-DDIInterventions: Drug: Riociguat (Adempas, BAY 63-2521); Drug: ATRIPLA; Drug: COMPLERA; Drug: STRIBILD; Drug: TRIUMEQ; Drug: Antiretroviral protease inhibitor Sponsor: Bayer Completed Tue, 22 Sep 2015 12:00:00 EDT
Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 YearsCondition: HIV-1 InfectionInterventions: Drug: E/C/F/TAF; Drug: TDF; Drug: FTC; Drug: FTC/TDF; Drug: 3TC; Drug: Third agent Sponsor: Gilead Sciences Completed Mon, 30 Nov 2015 12:00:00 EST |